enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has been given an average rating of “Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $33.67.
A number of equities research analysts recently weighed in on ENGN shares. Oppenheimer restated an “outperform” rating and issued a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th.
Read Our Latest Stock Report on enGene
Insiders Place Their Bets
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of ENGN. Logos Global Management LP grew its stake in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares in the last quarter. SR One Capital Management LP acquired a new stake in shares of enGene during the 2nd quarter worth approximately $4,715,000. Janus Henderson Group PLC bought a new position in enGene in the first quarter valued at approximately $17,095,000. Finally, Altitude Crest Partners Inc. bought a new position in enGene in the first quarter valued at approximately $2,039,000. Institutional investors own 64.16% of the company’s stock.
enGene Stock Down 3.0 %
enGene stock opened at $9.02 on Thursday. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $43.00. The firm has a market capitalization of $398.38 million, a PE ratio of -5.24 and a beta of -0.69. The company’s 50-day moving average is $6.71 and its 200-day moving average is $9.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52.
enGene (NASDAQ:ENGN – Get Free Report) last released its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. Sell-side analysts anticipate that enGene will post -1.56 earnings per share for the current year.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- The How and Why of Investing in Gold Stocks
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- 3 Fintech Stocks With Good 2021 Prospects
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.